Data as of Nov 28
| +0.60 / +0.83%|
Baxter International, Inc. develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions through its subsidiaries. It applies a combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. It operates business through two segments: BioScience and Medical Products. The BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; biosurgery products; and select vaccines. The Medical Products segment manufactures intravenous IV solutions and administration sets, premixed drugs and drug-reconstitution systems, prefilled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics. The business also provides products and services related to pharmacy compounding, drug formulation and packaging technologies. In addition, the Medical Products business provides products and services to treat end-stage renal disease, or irreversible kidney failure. It also manufactures solutions and other products for peritoneal dialysis, a home-based therapy, and also distributes products for hemodialysis, which is generally conducted in a hospital or clinic. Baxter International was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.
|Robert L. Parkinson||Chairman & Chief Executive Officer|
|Robert J. Hombach||Chief Financial Officer & Vice President|
|Paul E. Martin||Chief Information Officer & Vice President|
|Sebastian J. Bufalino||Vice President & Controller|
|Todd S. Young||Treasurer & Vice President|